BridgeBio expands board to 15, appoints Dr. Hannah Valantine as director effective Oct 23, 2021

BridgeBio Pharma, Inc.

Board of Directors expanded from 14 to 15 members; Dr. Hannah Valantine appointed as Class I director effective Oct 23, 2021.
Dr. Valantine received option to purchase $1,200,000 of common stock at $48.45 per share, vesting over three years.
She currently serves as Professor of Medicine at Stanford and was former Chief Officer for Scientific Workforce Diversity at NIH (2014-2020).
Dr. Valantine co-invented organ donor-derived cell-free DNA technology for transplant rejection monitoring.
She also serves on boards of Pacific Biosciences (PACB) and CareDx (CDNA).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Hannah A. Valantine

Director

BBIO · BridgeBio Pharma, Inc.

Effective: 2021-10-23
Filed: October 26, 2021, 7:59 PM ET

Effective as of October 23, 2021, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Dr. Hannah A. Valantine to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Hannah A. Valantine was appointed as Director at BridgeBio Pharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective as of October 23, 2021, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Dr. Hannah A. Valantine to the Board.

View on SEC.gov

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-307134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.